The phase 2 KEYNOTE-158 study was conducted to prove that the antitumor activity of pembrolizumab in patients with advanced cervical cancer demonstrated an ORR of 14.3% (complete response (CR) 2.6% and partial response (PR) 11.7%), and the ORR- of PD-L1-positive patients among all subjects was confirmed to be 16.0% [68]. This evidence concerns the gene CD274 and cervical cancer.